healthcare providers media publications & posters WE ARE KIADIS OUR RESEARCH FOCUS FOR INVESTORS KIADIS NEWS CAREERS Sanofi & Kiadis have joined forces to expand and accelerate the potential benefits of novel cell-based therapies to treat cancer patients FOR INVESTORS Sanofi Offers to Acquire Kiadis: Transaction Documents PRESS RELEASE Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings 15 Jul 2021 INVESTOR RELATIONS Sanofi Investor Relations Our uncompromising approach to serve patients, their families and care givers aims to minimize harm and maximize help – delivering personalized treatments for every single patient to offer hope, reduce suffering and provide new life. RESEARCH FOCUS Kiadis is focused on developing new cancer immunotherapeutics as well as novel adjunctive treatments for patients undergoing hematopoietic stem cell transplants. CAREERS Join our Team Employee Testimonials “I find it very exciting to be working on topics that can at times be controversial and also high risk. It allows us to be pioneers in the field and make a massive impact on research and medicine.” — Rana Nikzad, Senior Scientist, NK Cell Program PIPELINE LOCATIONS LEGAL DISCLAIMERS COOKIES CONTACT PRIVACY SITEMAP CODE OF ETHICS © Copyright 2021 Kiadis Pharma

Skip to main navigation Client secondary header healthcare providers media publications & posters We are kiadis WE ARE KIADIS Our Research focus OUR RESEARCH FOCUS Investor Relations FOR INVESTORS Kiadis news KIADIS NEWS Careers CAREERS Stock Information Historical Price Access denied You are not authorized to access this page. Client Footer Menu LOCATIONS LEGAL DISCLAIMERS COOKIES CONTACT PRIVACY SITEMAP © Copyright 2021 Kiadis Pharma